Sodium benzoate - SyneuRx

Drug Profile

Sodium benzoate - SyneuRx

Alternative Names: Benzoate - SyneuRx; NaBen; SND-11; SND-13

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator SyneuRx International (Taiwan) corp
  • Class Antifungals; Antipsychotics; Antiseptics; Benzoates
  • Mechanism of Action D amino acid oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Schizophrenia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Schizophrenia

Most Recent Events

  • 27 Dec 2016 Sodium benzoate is still in phase IIb/III trials for Schizophrenia (In adolescents, Adjuvant therapy) in USA (PO) (NCT01908192)
  • 31 Oct 2014 SyneuRx plans a phase IIb/III trial for negative symptoms of Schizophrenia (In adults, Adjuvant therapy) in USA (PO) (NCT02261519)
  • 01 Jul 2014 SyneuRx files an IND application with the US FDA in USA for negative symptoms of Schizophrenia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top